FDA Rejects Takeda’s Marketing Application for Esophagitis Therapy

The FDA has declined to approve Takeda Pharamceutical’s new drug application for TAK-721, developed to treat a chronic inflammatory disease of the esophagus known as eosinophilic esophagitis.
Source: Drug Industry Daily